Pemafibrate (DrugBank: Pemafibrate)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎［原発性胆汁性肝硬変 (~2017.3)］ | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000039350 | 2020/03/01 | 01/03/2020 | Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia | Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia - Clinical benefit of pemafibrate in patients with primary biliary cholangitis (PBC) with dyslipidemia | primary biliary cholangitis | pemafibrate for 12 months bezafibrate for 12 months | Shinshu University Faculty of Medicine, Department of Gastroenterology | NULL | Pending | 20years-old | 95years-old | Male and Female | 60 | Not selected | Japan |
| 2 | JPRN-JapicCTI-173728 | 05/10/2017 | 05/10/2017 | Pharmacokinetic study of K-877 in patients with Primary biliary cholangitis | Pharmacokinetic study of K-877 in patients with Primary biliary cholangitis | Primary biliary cholangitis | Intervention name : Pemafibrate INN of the intervention : Pemafibrate Dosage And administration of the intervention : Oral dose Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : - | Kowa Co., Ltd. | NULL | complete | 20 | BOTH | 8 | Phase 1 | Japan |